ARVNCAUTIOUS

Revenue Growth (YoY)

-91.7%

Higher than 3% of Healthcare sector peers

Updated 1078h ago

Sector Performance

3th percentile

ARVN

-91.7%

Sector Median

6.2%

Sector Avg

3.8%

📊

Deep Analysis

Revenue growth year-over-year (YoY) compares revenue in the most recent quarter to the same quarter one year earlier; a -91.7% figure means Arvinas's revenue shrank by over 91% from that prior period.

The healthcare sector median is 6.2% growth, and Arvinas sits at the 2nd percentile among its peers—only 2% of companies in the sector have worse revenue growth. The metric shows no trend because both the year-over-year change and quarter-over-quarter change are listed as N/A, and only a single historical value is provided. This combination of an extreme revenue decline with no trend data implies a high-risk situation: the company's current commercial performance is severely impaired, and there is no evidence of recent improvement or stabilization. The -91.7% figure directly supports the overall CAUTIOUS verdict, as collapsing revenue far below the sector median is a clear red flag for investors.

Frequently Asked Questions

What does the Revenue Growth (YoY) tell investors about ARVN?

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.

How is the Revenue Growth (YoY) calculated?

Revenue Growth (YoY) is calculated as: (Revenue_t - Revenue_t-4) / Revenue_t-4.

How does ARVN's Revenue Growth (YoY) compare to its sector?

ARVN's Revenue Growth (YoY) of -91.7% compares to a Healthcare sector median of 6.2%, placing it in the 3th percentile.

Who are ARVN's closest peers by Revenue Growth (YoY)?

The closest Healthcare peers by Revenue Growth (YoY) include: TMO (6.2%), AMGN (5.8%), CPRX (5.6%), HIMS (3.8%), BAX (2.9%).

The Formula

(Revenue_t - Revenue_t-4) / Revenue_t-4

Why It Matters

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.